Latest breakthroughs in cancer research, treatment, and prevention
643 articles
A UCLA study found that aggressive small cell cancers lacking the RB gene depend on protein E2F3 to survive — blocking it stopped tumor growth in lab models.
A new CAR T cell product called GCAR1 shows early clinical promise against rare, treatment-resistant solid tumors driven by gene fusions.
A mature phase III trial finds no survival difference between chemotherapy and radiotherapy as first-line treatment for low-grade glioma.
Peter Attia explains the science behind fasting as a tool to enhance chemotherapy efficacy while protecting healthy cells.
Science Translational Medicine publishes an erratum for a 2024 study on GDP-mannose and antitumor immunity in triple-negative breast cancer.
A correction to a landmark case-control study reexamines vitamin D's role in breast cancer risk among Saudi Arabian women.
USP20 drives immune exhaustion in pancreatic cancer by hijacking cholesterol and autophagy — and blocking it triples treatment response in preclinical models.
A lipid metabolism enzyme called SMPD1 anchors the deadliest cancer mutation to the cell membrane — and blocking it may finally crack KRAS.
A large multicenter study finds GLP-1 receptor agonists dramatically outperform DPP-4 inhibitors in preventing HCC recurrence and death post-resection.
The COMPETE trial shows radioligand therapy extends progression-free survival by nearly 10 months vs. standard targeted therapy in GEP NETs.
New research reveals how a high-fat diet rewires tumor-to-nerve communication, accelerating cachexia — the devastating wasting syndrome that kills cancer patients.
Harvard's COMPASS model forecasts which patients will respond to immune checkpoint inhibitors with striking accuracy across seven cancer types.
